5. 若針對「原發部位不明上皮癌」(CUP, carcinoma of unknown primary)的腫瘤檢體，進行次世代基因定序分析(NGS, next generation sequencing)，最常見發生基因變異(GA, genetic alterations)的基因為下列何者? (A) KRAS (B) CDKN2A (C) ARID1A (D) TP53 (E) MTOR

5. 若針對「原發部位不明上皮癌」(CUP, carcinoma of unknown primary)的腫瘤檢體，進行次世代基因定序分析(NGS, next generation sequencing)，最常見發生基因變異(GA, genetic alterations)的基因為下列何者?
(A) KRAS
(B) CDKN2A
(C) ARID1A
(D) TP53
(E) MTOR

答案：登入後查看
統計： A(12), B(5), C(1), D(53), E(3) #2128254

詳解 (共 1 筆)

B1 · 2021/03/24

#4615005

The mean number of G...

(共 132 字，隱藏中）

前往觀看

3. 一69歲男性，病理切片診斷確診罹患小細胞肺癌 (SCLC, small-cell lung cancer)，PET/CT掃描結果顯示右側肺門(hilar)部位有一4 x 5公分腫塊，且同側有中等量(moderate)的肋膜積水，經肋膜積水穿刺檢查，肋膜積水細胞學證實同樣有SCLC癌細胞。下列敘述何者為真? (A) Surgical therapy alone has a high curative rate for his stage of SCLC (B) Radiation plays no palliative role at all in therapy for this disease (C) Twenty percent of patients with SCLC are diagnosed with the same stage of disease as this patient (D) The majority of patients with SCLC of this stage respond to chemotherapy alone and go into remission with a very high 3-year survival (E) This patient has extensive-stage disease

5. 若針對「原發部位不明上皮癌」(CUP, carcinoma of unknown primary)的腫瘤檢體，進行次世代基因定序分析(NGS, next generation sequencing)，最常見發生基因變異(GA, genetic alterations)的基因為下列何者?
(A) KRAS
(B) CDKN2A
(C) ARID1A
(D) TP53
(E) MTOR

詳解 (共 1 筆)

相關試題

相關試卷

5. 若針對「原發部位不明上皮癌」(CUP, carcinoma of unknown primary)的腫瘤檢體，進行次世代基因定序 分析(NGS, next generation sequencing)，最常見發生 基因變異(GA, genetic alterations)的基因為下列何者? (A) KRAS (B) CDKN2A (C) ARID1A (D) TP53 (E) MTOR

詳解 (共 1 筆)

相關試題

相關試卷

5. 若針對「原發部位不明上皮癌」(CUP, carcinoma of unknown primary)的腫瘤檢體，進行次世代基因定序分析(NGS, next generation sequencing)，最常見發生基因變異(GA, genetic alterations)的基因為下列何者?
(A) KRAS
(B) CDKN2A
(C) ARID1A
(D) TP53
(E) MTOR